During the preclinical stage, Alzheimer’s disease (AD) pathologies—amyloid beta (Aβ) and tau—slowly aggregate in the brain and interact with other risk factors including anxiety and depression [8–10], eventually leading to cognitive decline and dementia [11]. Here, MAPT is linked to Alzheimer disease.